Developers of prescription digital therapeutics are encountering headwinds across European markets despite early regulatory frameworks designed to fast-track software-based medical interventions. Differences in country-specific health technology assessments remain a core barrier.
Reimbursement Friction
While early national initiatives provided blueprints for digital application coverage, neighboring healthcare systems have been slow to establish standardized reimbursement pathways. Developers must now conduct redundant clinical trials to satisfy localized cost-benefit criteria.